David A. Siegel Erasca, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Erasca, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 594,600 shares of ERAS stock, worth $820,547. This represents 0.0% of its overall portfolio holdings.
Number of Shares
594,600
Previous 793,200
25.04%
Holding current value
$820,547
Previous $2.17 Million
31.09%
% of portfolio
0.0%
Previous 0.01%
Shares
9 transactions
Others Institutions Holding ERAS
# of Institutions
153Shares Held
226MCall Options Held
10.9KPut Options Held
65.1K-
Frazier Life Sciences Management, L.P. Menlo Park, CA19.4MShares$26.8 Million2.92% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD16.7MShares$23.1 Million0.03% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$22.4 Million6.72% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$17.5 Million0.0% of portfolio
-
Logos Global Management LP San Francisco, CA12.5MShares$17.3 Million4.12% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $169M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...